In: Human Molecular Genetics, 2017, vol. 26, no. 3, p. 582-598
|
In: Brain, 2016, vol. 139, no. 5, p. 1587-1604
|
In: Plos one, 2011, vol. 6, no. 4, p. e18268
Background: Monoclonal antibodies and antibody fragments are powerful biotherapeutics for various debilitating diseases. However, high production costs, functional limitations such as inadequate pharmacokinetics and tissue accessibility are the current principal disadvantages for broadening their use in clinic. Methodology and Principal Findings: We report a novel method for the long-term ...
|
In: Acta Neuropathologica, 2012, vol. 123, no. 5, p. 653-669
|
In: Human Molecular Genetics, 2000, vol. 9, no. 5, p. 803-811
|
In: Human Molecular Genetics, 2014, vol. 23, no. 18, p. 4887-4905
|
In: Human Molecular Genetics, 2009, vol. 18, no. 5, p. 872-887
|
In: Human Molecular Genetics, 2003, vol. 12, no. 21, p. 2827-2836
|
In: Human Molecular Genetics, 2007, vol. 16, no. 6, p. 651-666
|